€80m · Other round · Healthtech · Paris, France
Paris-based HighLife has raised €80m in financing, equivalent to more than $90m, co-led by Andera Partners, Sofinnova Partners, Supernova Invest and Mérieux Equity Partners. New investors include the European Investment Bank, BNP Paribas Développement and Capricorn Partners, while existing backers also participated.
HighLife develops a transcatheter mitral valve replacement system for patients with serious mitral regurgitation who are not suitable for surgery or edge-to-edge repair. The company says the financing will accelerate commercial expansion in Europe and advance its US clinical development programme, including a pivotal study.
Financing the move from clearance to adoption
HighLife is crossing from device development into two costly phases at once: a European commercial rollout and a US pivotal programme. Its catheter-based system avoids open-heart surgery, but clinical adoption still depends on evidence, physician training and consistent procedures across specialist centres.
The financing therefore backs more than regulatory progress. HighLife must translate its CE-marked system into repeatable patient selection and outcomes while funding the US evidence needed for a larger market. For investors, the critical milestones are not only sales growth but enrolment, safety and efficacy data that can widen the pool of patients treated.
